Eloxx Pharmaceuticals ( (ELOX) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eloxx Pharmaceuticals has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to ongoing financial constraints that prevent the company from engaging its independent public accounting firm to review its unaudited financial statements. Eloxx Pharmaceuticals has not provided a specific timeline for when the delayed report will be filed. The company anticipates a significant increase in net loss and accumulated deficit for the quarter ended June 30, 2025, compared to the same period in the previous year. Additionally, there is substantial doubt about the company’s ability to continue as a going concern due to insufficient cash resources. The notification was signed by Sumit Aggarwal, the President and CEO, on August 14, 2025, indicating the company’s commitment to resolving these issues and maintaining compliance.
More about Eloxx Pharmaceuticals
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3
See more data about ELOX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money